GRI Bio Secures Patent Protection for Novel NKT Cell-Targeting Compounds Across Inflammatory Diseases
Key Insights
GRI Bio (search) received U.S. Patent No. 12,528,775 protecting novel compound compositions featuring pyrrolidine, piperidine, or azepane ring systems for immunomodulation.
The patent strengthens intellectual property protection for the company's Natural Killer T (NKT) cell-targeting platform addressing inflammatory, fibrotic, and autoimmune diseases (search).
The company maintains a library of over 500 proprietary compounds while advancing lead program GRI-0621 for idiopathic pulmonary fibrosis (search) treatment.
GRI Bio (search) has secured significant intellectual property protection for its innovative approach to treating inflammatory diseases (search) through Natural Killer T (NKT) cell modulation. The U.S. Patent and Trademark Office issued Patent No. 12,528,775 on January 26, 2026, covering novel compound compositions that represent a key advancement in the company's immunomodulator platform.
Novel Molecular Architecture Drives Patent Protection
The newly issued patent includes composition-of-matter claims covering a distinct class of proprietary compounds defined by linked molecular structures that form pyrrolidine, piperidine, or azepane ring systems. These specific molecular configurations represent a key structural advancement and are separate and distinct from patents previously issued to the company, further strengthening the durability of GRI Bio (search)'s intellectual property estate.
"This patent reflects our disciplined IP strategy and scientific depth," said Marc Hertz, Chief Executive Officer of GRI Bio (search). "We have now secured independent protection for a novel and highly valuable subset of our chemistry platform."
NKT Cell Biology as Therapeutic Target
The patent supports GRI Bio (search)'s broader platform focused on modulating Natural Killer T (NKT) cell biology and complements the company's ongoing development of immune cell-targeted therapies for inflammatory, fibrotic, and autoimmune diseases (search). NKT cells (search) are innate-like T cells that share properties of both NK and T cells and serve as a functional link between the innate and adaptive immune responses.
Type I invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio (search)'s therapies are designed to target the activity of these cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis.
Lead Program and Pipeline Development
GRI Bio (search)'s lead program, GRI-0621, is an RARβγ (search) agonist shown to inhibit the activity of key immune cells, including iNKT cell activity, and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis (search), a serious disease with significant unmet need. The company is also developing a pipeline of novel type 2 diverse NKT (dNKT) agonists for the treatment of systemic lupus erythematosus (search).
With a library of over 500 proprietary compounds, GRI Bio (search) has the ability to fuel a growing pipeline while leveraging its growing chemistry platform to support future pipeline expansion and potential strategic partnerships. The company remains focused on advancing its lead program while utilizing this expanded intellectual property protection to strengthen its competitive position in the immune cell modulation space.